Fulgent Genetics, Inc.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Ming Hsieh
- Full Time Employees
- 1,184
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 4978 Santa Anita Avenue Temple City CA United States of America 91780
- IPO Date
- Sep 29, 2016
- CIK
- 0001674930
- Website
- fulgentgenetics.com
- Similar Companies
- Business
- Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Company News
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
Fulgent Reports Second Quarter 2024 Financial Results
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
Fulgent Reports First Quarter 2024 Financial Results
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
The 3 Best Digital Health Stocks for Personalized Medicine
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference